Quality control assessment for the serological diagnosis of tick borne encephalitis virus infections

Matthias Niedrig, Tatjana Avšič, Stephan W. Aberle, Emöke Ferenczi, Milan Labuda, Baiba Rozentale, Oliver Donoso Mantke

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The diagnosis of tick borne encephalitis (TBE) is mainly based on the demonstration of specific antibodies in serum when neurological disease is manifested. Improving diagnostics is the most important step in detecting and dealing with these pathogens. Quality control measures are essential for TBE diagnosis. Objective: To assess an external quality assurance (EQA) program for the serologic diagnosis of TBE infections. Study design: A panel of 12 serum samples was sent out to be tested for the presence of TBE virus-specific IgM and IgG. This panel contained seven TBE-positive samples for IgM and/or IgG; three negative samples; two samples positive either for West Nile virus (WNV) or Dengue virus (DENV). Results: Fourty-two laboratories from 25 European and 2 non-European countries participated in this EQA. The correct answer by each laboratory for all samples ranked between 58 and 96% and sera with IgM antibody positive for TBE were correctly recognized by 46-88% of the laboratories. Sera with IgG antibody positive for TBE were correctly recognized by 83-95% of the laboratories. False TBE-positive results were obtained with DENV, WNV or negative sera only for IgG-based assays. Conclusion: Correct results for at least 90% of the samples were obtained by 33 of 40 participating laboratories for IgM and for 16 of 42 laboratories for IgG.

Original languageEnglish
Pages (from-to)260-264
Number of pages5
JournalJournal of Clinical Virology
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Tick-Borne Encephalitis Viruses
Tick-Borne Encephalitis
Virus Diseases
Quality Control
Immunoglobulin G
Immunoglobulin M
West Nile virus
Serum
Dengue Virus
Antibodies
Tick-Borne Diseases
Infectious Encephalitis

Keywords

  • Arbovirus diagnostics
  • External quality assurance: EQA
  • Tick borne encephalitis

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Quality control assessment for the serological diagnosis of tick borne encephalitis virus infections. / Niedrig, Matthias; Avšič, Tatjana; Aberle, Stephan W.; Ferenczi, Emöke; Labuda, Milan; Rozentale, Baiba; Donoso Mantke, Oliver.

In: Journal of Clinical Virology, Vol. 38, No. 3, 03.2007, p. 260-264.

Research output: Contribution to journalArticle

Niedrig, Matthias ; Avšič, Tatjana ; Aberle, Stephan W. ; Ferenczi, Emöke ; Labuda, Milan ; Rozentale, Baiba ; Donoso Mantke, Oliver. / Quality control assessment for the serological diagnosis of tick borne encephalitis virus infections. In: Journal of Clinical Virology. 2007 ; Vol. 38, No. 3. pp. 260-264.
@article{55e3e8c4febf42b9a84ebd72b9c31624,
title = "Quality control assessment for the serological diagnosis of tick borne encephalitis virus infections",
abstract = "Background: The diagnosis of tick borne encephalitis (TBE) is mainly based on the demonstration of specific antibodies in serum when neurological disease is manifested. Improving diagnostics is the most important step in detecting and dealing with these pathogens. Quality control measures are essential for TBE diagnosis. Objective: To assess an external quality assurance (EQA) program for the serologic diagnosis of TBE infections. Study design: A panel of 12 serum samples was sent out to be tested for the presence of TBE virus-specific IgM and IgG. This panel contained seven TBE-positive samples for IgM and/or IgG; three negative samples; two samples positive either for West Nile virus (WNV) or Dengue virus (DENV). Results: Fourty-two laboratories from 25 European and 2 non-European countries participated in this EQA. The correct answer by each laboratory for all samples ranked between 58 and 96{\%} and sera with IgM antibody positive for TBE were correctly recognized by 46-88{\%} of the laboratories. Sera with IgG antibody positive for TBE were correctly recognized by 83-95{\%} of the laboratories. False TBE-positive results were obtained with DENV, WNV or negative sera only for IgG-based assays. Conclusion: Correct results for at least 90{\%} of the samples were obtained by 33 of 40 participating laboratories for IgM and for 16 of 42 laboratories for IgG.",
keywords = "Arbovirus diagnostics, External quality assurance: EQA, Tick borne encephalitis",
author = "Matthias Niedrig and Tatjana Avšič and Aberle, {Stephan W.} and Em{\"o}ke Ferenczi and Milan Labuda and Baiba Rozentale and {Donoso Mantke}, Oliver",
year = "2007",
month = "3",
doi = "10.1016/j.jcv.2006.12.013",
language = "English",
volume = "38",
pages = "260--264",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Quality control assessment for the serological diagnosis of tick borne encephalitis virus infections

AU - Niedrig, Matthias

AU - Avšič, Tatjana

AU - Aberle, Stephan W.

AU - Ferenczi, Emöke

AU - Labuda, Milan

AU - Rozentale, Baiba

AU - Donoso Mantke, Oliver

PY - 2007/3

Y1 - 2007/3

N2 - Background: The diagnosis of tick borne encephalitis (TBE) is mainly based on the demonstration of specific antibodies in serum when neurological disease is manifested. Improving diagnostics is the most important step in detecting and dealing with these pathogens. Quality control measures are essential for TBE diagnosis. Objective: To assess an external quality assurance (EQA) program for the serologic diagnosis of TBE infections. Study design: A panel of 12 serum samples was sent out to be tested for the presence of TBE virus-specific IgM and IgG. This panel contained seven TBE-positive samples for IgM and/or IgG; three negative samples; two samples positive either for West Nile virus (WNV) or Dengue virus (DENV). Results: Fourty-two laboratories from 25 European and 2 non-European countries participated in this EQA. The correct answer by each laboratory for all samples ranked between 58 and 96% and sera with IgM antibody positive for TBE were correctly recognized by 46-88% of the laboratories. Sera with IgG antibody positive for TBE were correctly recognized by 83-95% of the laboratories. False TBE-positive results were obtained with DENV, WNV or negative sera only for IgG-based assays. Conclusion: Correct results for at least 90% of the samples were obtained by 33 of 40 participating laboratories for IgM and for 16 of 42 laboratories for IgG.

AB - Background: The diagnosis of tick borne encephalitis (TBE) is mainly based on the demonstration of specific antibodies in serum when neurological disease is manifested. Improving diagnostics is the most important step in detecting and dealing with these pathogens. Quality control measures are essential for TBE diagnosis. Objective: To assess an external quality assurance (EQA) program for the serologic diagnosis of TBE infections. Study design: A panel of 12 serum samples was sent out to be tested for the presence of TBE virus-specific IgM and IgG. This panel contained seven TBE-positive samples for IgM and/or IgG; three negative samples; two samples positive either for West Nile virus (WNV) or Dengue virus (DENV). Results: Fourty-two laboratories from 25 European and 2 non-European countries participated in this EQA. The correct answer by each laboratory for all samples ranked between 58 and 96% and sera with IgM antibody positive for TBE were correctly recognized by 46-88% of the laboratories. Sera with IgG antibody positive for TBE were correctly recognized by 83-95% of the laboratories. False TBE-positive results were obtained with DENV, WNV or negative sera only for IgG-based assays. Conclusion: Correct results for at least 90% of the samples were obtained by 33 of 40 participating laboratories for IgM and for 16 of 42 laboratories for IgG.

KW - Arbovirus diagnostics

KW - External quality assurance: EQA

KW - Tick borne encephalitis

UR - http://www.scopus.com/inward/record.url?scp=33847047886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847047886&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2006.12.013

DO - 10.1016/j.jcv.2006.12.013

M3 - Article

C2 - 17267281

AN - SCOPUS:33847047886

VL - 38

SP - 260

EP - 264

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 3

ER -